IE-RAD2020 License Technology of Claritas HealthTech Pte. Ltd. entered into a purchase agreement to acquire Labrador Technologies Inc. (TSXV:LTX), in a reverse merger transaction for CAD 5 million on June 28, 2020. The agreement gives Labrador exclusive usage and marketing rights to the license software for the territory of North America in return for the issuance of 50 million shares in Labrador at a deemed price of CAD 0.10 per share on a post consolidated 20 to 1 basis. As of August 12, 2020, Labrador Technologies completed the share consolidation. In a related transaction, Claritas will undertake a private placement of subscription receipts of units for minimum gross proceeds of CAD 2.5 million up to a maximum of CAD 5 million. Churchgate Singapore Ltd. will provide Labrador CAD 0.15 million as bridge financing of units of Claritas to cover costs associated with the transaction. As of July 21, 2020, Labrador closed its convertible debenture bridge financing for gross proceeds of CAD 0.15 million. Upon the closing of the transaction, it is expected that Labrador will continue to be a technology issuer on the TSXV and will be renamed to Claritas HealthTech Inc. Upon completion, Devika M. Dutt will become the Chief Executive Officer and Director, Nikhil Kamran will become the Chief Financial Officer, Kaan Camlioglu will become the Chief Operating Officer and Director, Shravan Joshi along with Laszlo Neumann will become Directors and Bill deJong will become the corporate secretary. The transaction is not subject to the approval of the shareholders of Labrador. However, the shareholder’s approval is required for the appointment of new board of directors of Labrador and approval to change the name and trading symbol of Labrador upon completion of the transaction. The transaction is subject to disinterested shareholder approval, closing conditions customary, approvals of all regulatory bodies having jurisdiction, TSXV regulatory approval, debt reduction of payables outstanding and the completion of raising the minimum amount for the private placement and completion of the bridge financing. As of January. 22, 2021, TSX Venture Exchange has conditionally approved the reverse take-over transaction. As of June 24, 2021, the expected closing date is extended to July 15, 2021. Computershare Trust Company of Canada acted as transfer agent for Labrador. IE-RAD2020 License Technology of Claritas HealthTech Pte. Ltd. cancelled the acquisition of Labrador Technologies Inc. (TSXV:LTX), in a reverse merger transaction on July 16, 2021. The transaction will not be proceeding as conditions to closing have not been met by the outside closing date of July 15, 2021.